# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN-TD
- Date: 1989-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-month HIV and coronary disease review with depression screening. **S**

## History of present illness

Mr. Ashe returns six months after his first visit. He has missed no doses. He has had no headache, weakness, rash, fever, or chest pain, and has not needed nitroglycerin. He is back to full-time writing and coaching. He gave a urine sample with this morning's blood tests. He answered the PHQ-9 with a score of 2 and has no thoughts of self-harm. He says that knowing his viral load is undetectable has eased his mind. **S**

| Element | Detail |
|---|---|
| Adherence | No missed doses |
| Work | Full-time writing and coaching |
| Mood | PHQ-9 2; item 9 scored 0 |
| Heart | No angina; nitroglycerin not used |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; weight up 0.8 kg |
| Cardiovascular | Negative | No chest pain or palpitations |
| Neurological | Negative | No headache, seizure, or weakness |
| Psychiatric | Negative | Mood good; PHQ-9 score 2; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 66 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 74.6 kg; BMI 21.8 kg/m². All vital signs are synthetic.

HIV-1 viral load: 0 {copies}/mL; CD4 count: 262 /uL (low); Sodium: 140 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.14 mg/dL; eGFR: 80 mL/min/1.73 m²; Glucose: 93 mg/dL; Urine albumin-to-creatinine ratio: 12 mg/g; PHQ-9: 2. All results are synthetic.

## Change since baseline

- HIV-1 viral load: 42 {copies}/mL (high) at baseline, 0 {copies}/mL at this visit **S**
- CD4 count: 156 /uL (low) at baseline, 262 /uL (low) at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.9 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.14 mg/dL at this visit **S**
- eGFR: 78 mL/min/1.73 m² at baseline, 80 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 93 mg/dL at this visit **S**
- PHQ-9: 5 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 74.6 kg, blood pressure 118/72 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | No focal deficit |

All examination findings are synthetic. **S**

## Assessment and plan

1. **HIV infection** (B20). Viral load not detected for the second time; CD4 count 262. Potassium 4.6 mmol/L, creatinine 1.14 mg/dL. Urine albumin-to-creatinine ratio 12 mg/g, normal, closing the deviation recorded at the earlier visits. **S**
   - Continue the same regimen.
   - Viral load, CD4 count, blood count, and metabolic panel at nine months.
   - Urine albumin yearly.
2. **Cerebral toxoplasmosis on maintenance therapy** (B58.2). No symptoms; CD4 above 200 for three months. **S**
   - Continue trimethoprim-sulfamethoxazole; if the CD4 count is still above 200 at nine months, stop it.
3. **Coronary artery disease after two bypass operations** (I25.10). No angina; blood pressure at goal; LDL 52 mg/dL three months ago. PHQ-9 2. **S**
   - Continue aspirin, atorvastatin, and ezetimibe.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HIV-1 viral load | 4 to 8 weeks after starting ART, every 4 to 8 weeks until suppressed, then every 3 months | Completed today | Not detected (below 20 copies/mL), the second undetectable result |
| Laboratory | CD4 count | Every 3 months while below 200 and on prophylaxis; every 3 to 6 months in the first 2 years of ART | Completed today | 262 cells/uL |
| Medication safety | ART adherence and drug-interaction review (antacids, calcium, iron, new medicines) | Every visit | Completed today | No missed doses; no interacting medicines |
| Laboratory | Complete blood count | Every 3 months on trimethoprim-sulfamethoxazole; every 3 to 6 months on ART | Up to date | Normal three months ago; next at nine months |
| Laboratory | Potassium, creatinine, and eGFR | 1 to 4 weeks after starting trimethoprim-sulfamethoxazole, then every 3 to 6 months | Completed today | Potassium 4.6 mmol/L, creatinine 1.14 mg/dL, eGFR 80 |
| Laboratory | Urine albumin-to-creatinine ratio on tenofovir | At the start of tenofovir and yearly | Completed today | Albumin-to-creatinine ratio 12 mg/g, normal; collected late after the deviations recorded at four weeks and three months; no harm resulted |
| Laboratory | ALT | Every 6 months on ART; with symptoms on a statin | Up to date | ALT 27 U/L three months ago |
| Medication safety | Toxoplasma maintenance therapy and stopping criteria | Continue until CD4 above 200 for more than 6 months on ART with a suppressed viral load | Completed today | CD4 above 200 for three months; continue to nine months |
| Medication safety | Pneumocystis prophylaxis | While CD4 below 200; stop after more than 3 months above 200 | Completed today | CD4 above 200 for three months; covered by the maintenance dose, which continues |
| Examination | Neurological check: headache, seizure, weakness, and right-hand strength | Every visit | Completed today | No symptoms |
| Self-management | Recombinant zoster vaccine | Two doses 2 to 6 months apart, from age 18 with HIV | Due | Dose 2 at the preventive visit next month |
| Self-management | Psychosocial support, disclosure on his terms, and U=U counseling | Every visit | Completed today | Reassured by his undetectable results; disclosure remains his decision |
| Survey | Depression screen (PHQ-9 or PHQ-2) | At intake, at six months, and yearly | Completed today | PHQ-9 2, with item 9 scored 0 |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 118/72 mmHg |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 74.6 kg, BMI 21.8; full-time work and exercise three times a week |
| Self-management | Tobacco use | Every visit | Completed today | Never used tobacco |
| Medication safety | Coronary medicine adherence: aspirin 81 mg, high-intensity statin, ezetimibe | Every visit | Completed today | Taking all three |
| Self-management | Angina review and chest-pain plan | Every visit | Completed today | No angina |
| Laboratory | Lipid panel | 4 to 12 weeks after a change, then every 3 to 12 months; yearly when stable | Up to date | LDL 52 mg/dL three months ago; yearly from now on |
| Imaging | Stress testing, coronary imaging, or echocardiography | Only with new or worsening symptoms; routine surveillance not recommended | Not indicated | No symptoms |

## Goal progress

- HIV-1 viral load not detected by the three-month visit. Outcome by 1989-04-13: Viral load not detected (below 20 copies/mL) at three months, and at six and nine months. **S**
- CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely. In progress; target 1989-10-19. **S**
- LDL cholesterol below 55 mg/dL by the three-month visit. Outcome by 1989-04-13: LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe. **S**
- Hepatitis B vaccine series completed with a protective antibody level by the three-month visit. Outcome by 1989-04-13: Hepatitis B surface antibody 86 mIU/mL. **S**
- Keep blood pressure below 130/80 mmHg. Outcome by 1989-07-13: Blood pressure 116 to 120 over 72 to 74 at every visit. **S**

## Guideline basis

- Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition), U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents
- Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition), National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024), International Antiviral Society-USA (JAMA)
- Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020), HIV Medicine Association of the Infectious Diseases Society of America (Clinical Infectious Diseases)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Preventive visit next month with the second zoster dose. Nine-month HIV review with blood tests. **S**
- Next scheduled visit 1989-08-17: periodic adult preventive visit. **S**
